MedPath

Prevention of Inappropriate Therapies and MACCE With a Single Chamber ICD With DX Floating Dipole Atrial Detection

Conditions
Prevention of Inappropriate Therapies and MACCE. Single-chamber ICD
Interventions
Other: Single chamber DAI device with floating atrial dipole
Registration Number
NCT04344704
Lead Sponsor
Trialance SCCL
Brief Summary

Prevention of inappropriate therapies and serious adverse cardiac and cerebrovascular events with a single chamber implantable defibrillator with DX floating dipole atrial detection

Detailed Description

Prospective, randomized, open-label, multicenter, international study in a population with an accepted indication for an implantable automatic defibrillator.

The main objective is to know the different values of the rates of inappropriate therapies, of serious cardiac and cerebrovascular adverse events, and of the appropriate detections in single-chamber ICD devices, with optimized programming according to the patient's arrhythmic history, using the three discrimination methods. arrhythmias: Smart, Onset and Stability, and Morphmatch.

The device under investigation is a single chamber with a floating atrial dipole for the detection of atrial signals.

Patients who are included in the study will present an indication for an automatic cardioverter-defibrillator device according to clinical practice guidelines for an ICD and who also do not have an indication for permanent stimulation in the right atrium. For this reason, the indication of patients will be those that require an ICD without the implantation of an electrode in the atrium, that is, single-chamber ICDs or DX ICDs since both, from the therapeutic point of view, are equivalent.

The centers will follow standard clinical practice to diagnose patients

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
462
Inclusion Criteria
  • Patients with an indication of a single chamber ICD due to high risk of sudden death.
  • Patients with and without a prior history of AF.
  • Patients with indication for primary and secondary prevention.
  • Device optimized for the discrimination of supraventricular events.
  • DX device implant with single floating cable.
  • Activation of "Home Monitoring" function.
  • Over 18 years.
  • Signature of informed consent
Exclusion Criteria
  • Indication for permanent atrial pacing according to current pacing guidelines.
  • Congestive heart failure grade IV.
  • Candidates for Cardiac Resynchronization Therapy.
  • Patients with a previous device.
  • Permanent Atrial Fibrillation.
  • Life expectancy less than 12 months.
  • Pregnant or lactating women.
  • Patients who are unable to understand the nature of the study.
  • Subjects with irreversible brain damage caused by pre-existing brain disease.
  • Heart transplant 6 months prior to recruitment or expected in the next 3 months.
  • Cardiac surgery 3 months prior to recruitment or planned for the next 3 months.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
DX device programmed in single chamber modeSingle chamber DAI device with floating atrial dipolewith the activation of one of the available discrimination criteria: * Onset: distinguishes slow onset or onset tachycardias from sudden onset * Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring. * Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width
DX devices with SMART headset detection enabledSingle chamber DAI device with floating atrial dipoleThe SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
Primary Outcome Measures
NameTimeMethod
The combined rate of inappropriate therapies and serious adverse cardiac and cerebrovascular events (MACCE) single-chamber devices with floating atrial dipole with the Smart function activated24 months

determine the combined rate is not less than in single-chamber devices without atrial detection using any of the supraventricular arrhythmia discrimination modalities: Onset and Stability, and Morphmatch.

Secondary Outcome Measures
NameTimeMethod
Inappropriate therapies distribution24 months

According to the type of indication for an ICD in primary and secondary prevention

Programming adjustment justification24 months

Adjustments suggested by the European Heart Rhythm Association

Appropriate therapies by group and by indication24 months

Portion of appropriate therapies

Proportion of appropriate and inappropriate diagnoses24 months

By diagnosis group

Percentage of patients with clinical AF (atrial fibrillation) versus subclinical AF (<6 minutes duration).24 months

Clinical AF meaning \> 6 minutes duration and subclinical AF meaning \<6 minutes duration

Distribution of inappropriate therapies by chosen schedule24 months
Differences in events according to Onset & Stability method versus Morphmatch method24 months

Events in single chamber programming without floating dipole

Triggers of Inappropriate therapies24 months
Patients presenting atrial fibrillation before inclusion24 months

percentage

Patients with no prior history of atrial fibrillation (AF) who have AF during study follow-up24 months

Percentage

General atrial load in patients with and without previous manifestation of atrial fibrillation24 months
Cerebrovascular events presenting previous episodes of atrial fibrillation24 months

Rate

Trial Locations

Locations (16)

Hospital Universitario Josep Trueta

🇪🇸

Girona, Spain

Hospital San Pedro

🇪🇸

Logroño, Spain

Hospital Universitario Virgen de la Victoria

🇪🇸

Málaga, Spain

Hospital Universitario de Araba

🇪🇸

Gasteiz / Vitoria, Alava, Spain

Hospital Universitario Puerta de Hierro

🇪🇸

Majadahonda, Madrid, Spain

Hospital Universitario de Donostia

🇪🇸

Donostia, Guipúzcoa, Spain

Complejo Hospitalario Universitario A Coruña

🇪🇸

A Coruña, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Universitario de Tarragona Joan XXIII

🇪🇸

Tarragona, Spain

Hospital Universitario y Politécnico La Fe

🇪🇸

Valencia, Spain

Hospital Universitario de Bellvitge

🇪🇸

L'Hospitalet De Llobregat, Barcelona, Spain

Hospital Universitario Clínico de Santiago

🇪🇸

Santiago De Compostela, A Coruña, Spain

Hospital Álvaro Cunqueiro

🇪🇸

Vigo, Pontevedra, Spain

Hospital Universitario Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

Complejo Hospitalario Universitario de Canarias

🇪🇸

Santa Cruz De Tenerife, Tenerife, Spain

Hospital Clínico y Universitario de Valladolid

🇪🇸

Valladolid, Spain

© Copyright 2025. All Rights Reserved by MedPath